Zevra Therapeutics (ZVRA) Cash from Investing Activities Growth (3y) (2017 - 2026)
Zevra Therapeutics (ZVRA) Cash from Investing Activities Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -29.84% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 38.24% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -22.09% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Zevra Therapeutics | 570.04 Mn | 369.43 Mn | 34.32 Mn | 86.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86.96% |
| Dec 31, 2025 | 77.61% |
| Sep 30, 2025 | -166.01% |
| Jun 30, 2025 | 33.15% |
| Mar 31, 2025 | 67.98% |
| Dec 31, 2024 | 29.24% |
| Sep 30, 2024 | -1,886.45% |
| Jun 30, 2024 | -16.78% |
| Dec 31, 2023 | 642.36% |
| Jun 30, 2023 | 1,941.55% |
| Mar 31, 2023 | -1,068.61% |
| Dec 31, 2022 | -132.70% |
| Sep 30, 2022 | 312.13% |
| Mar 31, 2022 | -47.15% |
| Dec 31, 2021 | -57.92% |
| Sep 30, 2021 | -26.18% |
| Jun 30, 2021 | -26.10% |
| Dec 31, 2020 | -26.05% |
| Jun 30, 2020 | -91.28% |
| Mar 31, 2020 | -26.03% |